SCHEMBL10242035

SCHEMBL10242035

Cc1cc(NC(=O)Nc2ccccc2)ccc1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.59
MAOB P27338 2/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
TP53 P04637 2/20 0.59
EPHX1 P07099 1/20 0.59
TSHR P16473 1/20 0.59
EPHX2 P34913 1/20 0.59
CDK9 P50750 1/20 0.59
CLK4 Q9HAZ1 1/20 0.59
CXCR2 P25025 1/20 0.58
KMT2A Q03164 6/20 0.58
NPC1 O15118 5/20 0.58
RAB9A P51151 5/20 0.58
TAAR1 Q96RJ0 2/20 0.58
MAPT P10636 5/20 0.57
MEN1 O00255 5/20 0.57
LMNA P02545 2/20 0.57
MAPK1 P28482 2/20 0.57
CASP3 P42574 1/20 0.56
SENP7 Q9BQF6 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7093860 0.86 KMT2A (0.61) MAOAMAOBSMN1; SMN2TP53EPHX1
SCHEMBL18155290 0.86 ALOX15 (0.55) SMN1; SMN2TP53KMT2ANPC1RAB9A
SCHEMBL13772128 0.84 ALOX15 (0.71) MAOAMAOBSMN1; SMN2TP53EPHX1
SCHEMBL4686246 0.83 HSP90AA1 (0.53) TP53TSHRKMT2ANPC1RAB9A
SCHEMBL10242032 0.83 CYP1A2 (0.69) MAOAMAOBSMN1; SMN2KMT2ANPC1
SCHEMBL11563350 0.82 POLB (0.53) TSHRKMT2ANPC1RAB9AMAPT
SCHEMBL23292684 0.81 CYP1A2 (0.71) MAOAMAOBSMN1; SMN2TP53EPHX1
SCHEMBL3460205 0.81 SMN1; SMN2 (0.57) MAOAMAOBSMN1; SMN2TP53EPHX1
SCHEMBL10242069 0.81 KMT2A (0.71) SMN1; SMN2TP53KMT2ANPC1RAB9A
SCHEMBL23292687 0.80 CNR1 (0.62) MAOAMAOBSMN1; SMN2TP53EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022045365-A1 POLYPEPTIDE CONTAINING FIBRONECTIN TYPE III DOMAIN SCAFFOLD 国立大学法人東海国立大学機構 2022-03-03 WO disclosed
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 US disclosed
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 US disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 US disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 US disclosed
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2010-10-28 US disclosed
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2010-10-28 US disclosed
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-07-30 US disclosed
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-07-30 US disclosed
US-20080318956-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2008-12-25 US disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 US disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 US disclosed
EP-1847263-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-24 EP disclosed
EP-1844766-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-17 EP disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090779-A1 ANTIALLERGIC AGENTS NAT1, EPX, HRH2 MAOA 12/4885MAOB 64/4885SMN1; SMN2 4693/4885
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A MAOA 951/4885MAOB 819/4885SMN1; SMN2 4852/4885
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A MAOA 890/4885MAOB 701/4885SMN1; SMN2 4859/4885
US-20080318956-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A MAOA 890/4885MAOB 701/4885SMN1; SMN2 4859/4885
US-20070185110-A1 Antiallergic agents NAT1, EPX, AHR MAOA 7/4885MAOB 56/4885SMN1; SMN2 4695/4885
US-20070185059-A1 Antiallergic agents NAT1, EPX, AHR MAOA 10/4885MAOB 60/4885SMN1; SMN2 4709/4885
US-20070042997-A1 Medicament for treatment of dermal pigmentation TYR, XDH, XPA MAOA 7/4885MAOB 19/4885SMN1; SMN2 4614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.